Amgen, the US-based biopharmaceutical giant, may be gearing up to submit a fresh approach for Alexion Pharmaceuticals but there is division over what price it previously offered for its smaller rival.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
